IRIS Testing for Diabetic Retinopathy
Provider 
Founded 1997
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public

IRIS retinal imaging technology supports diabetic retinopathy screening and specialist interpretation.
Biomedix offers IRIS technology to help identify diabetic retinopathy through fundus-image analysis. Its camera-agnostic platform captures retinal images and connects them with ophthalmologic specialists for interpretation.
The imaging tools enhance vessel and nerve-fiber details to help providers review scans for potential pathology. The IRIS specialist network returns interpretations to providers, and its solution integrates with Biomedix Xchange for chronic-condition tracking.
Adds products that compete with one of IRIS Testing for Diabetic Retinopathy’s direct competitors but not with IRIS Testing for Diabetic Retinopathy itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | IRIS Testing for Diabetic Retinopathy | LumineticsCore | AEYE Diagnostic Screening (AEYE-DS) | |
|---|---|---|---|---|
| Linked Through | — | Direct competitor | LumineticsCore | |
| Provider | ||||
| Founded | 1997 | 2010 | 2018 | |
| Sells To | Enterprise | B2B, Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Licensing, Recurring, Software | Recurring, Software | |
| Ownership | Public | Private | Venture-backed |
Provider 
Founded 1997
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2010
Sells To B2B, Enterprise
Pricing Model Licensing, Recurring, Software
Ownership Private
Linked Through LumineticsCore
Provider 
Founded 2018
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed


AEYE Diagnostic Screening is an autonomous AI product for point-of-care diabetic retinopathy screening by healthcare providers.
AEYE Diagnostic Screening is an autonomous AI product for point-of-care diabetic retinopathy screening by healthcare providers.
